SIRT3 and lung carcinoma: SIRT3 promotes the doxorubicin (DOX)-resistance of lung cancer cells by enhancing autophagy to counteract DOX-induced senescence primarily through the inhibition of PI3K/AKT/mTOR signaling 72.